Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bispecific CD19-CD22 CAR-T in R/R B-ALL
NCT04034446Phase 1Terminated
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2019
- Primary completion
- Jul 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital) in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Treatment-related adverse events at 24 months and Overall Remission Rate at 3 months. Started Sep 2019; status: terminated.
02
Drugs
CD19-CD22 CAR-T cells (Shanxi Province Cancer Hospital)
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04034446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034446.